Clinical stage focus Position Embera as a clinical‑stage biotech with ongoing R&D in addiction treatments, highlighting opportunities to partner on late‑stage trials, specialized clinical services, or co‑development deals with CROs and contract manufacturers that support scalable manufacturing for trial materials.

Strategic funding history Leverage a track record of early funding and NIH/NIDA grant support to approach philanthropic foundations, government programs, and venture groups for follow‑on investment or milestone‑driven partnerships, emphasizing credibility and growth potential to investors and strategic buyers.

Key leadership signals Engage with current and recent board and executive hires (board member from Aisling Capital, new CMO) as potential champions for partnerships, licensing discussions, or advisory roles, and tailor value propositions to their strategic interests in drug development and regulatory progress.

Boston biotech hub Target proximity to the greater Boston ecosystem for in‑person business development, identifying nearby CROs, contract manufacturers, and academic collaborators to accelerate trials, provide manufacturing support, or co‑develop commercial strategies in addiction therapies.

Portfolio support needs Highlight potential need for GMP manufacturing, supply chain, and translational services for addiction programs; propose bundled services from potential vendors (CMC, QA, logistics) to reduce time to clinic and improve trial readiness and regulatory submissions.